Publications by authors named "Sasa Pockar"
Article Synopsis
- Pediatric uveitis is a rare but serious eye condition requiring prompt treatment to prevent vision loss, often using adalimumab (ADA) when other medications are ineffective.
- This study looked at 42 pediatric patients over six months at the Manchester Royal Eye Hospital, analyzing their previous treatments, how long they had uveitis before starting ADA, and the drug's effectiveness.
- The results showed that 78% of patients achieved complete control of inflammation on ADA, with most responding within six months, although some developed anti-drug antibodies which affected treatment outcomes.
Purpose: To evaluate the long-term visual outcomes of patients with uveitis undergoing cataract surgery and to identify possible factors influencing the visual prognosis and the development of postoperative complications.
Methods: Retrospective study of all patients with uveitis who underwent cataract surgery between January 2015 and February 2020 in our tertiary referral center.
Results: A total of 78 eyes from 78 patients were included in the study.
Article Synopsis
- Noninfectious uveitis (NIU) in children is a rare but treatable condition that can lead to vision loss, necessitating careful monitoring and management.
- Treatment options include systemic methods like corticosteroids and disease-modifying drugs, with a stepwise approach being common; methotrexate is the preferred conventional drug, while adalimumab is the only approved biological treatment for kids.
- Managing pediatric NIU requires a multidisciplinary team to address medical, psychological, and supportive needs, including dealing with potential side effects and treatment responses.
Purpose: To describe a case of interferon-beta retinopathy associated with paracentral acute middle maculopathy.
Case Report: A 15-year-old girl with Epstein-Barr virus-positive advanced nasopharyngeal carcinoma WAS REFERRED with reduced visual acuity. Multimodal imaging findings, including optical coherence tomography angiography, at presentation and evolution following cessation of interferon therapy are presented.
Aim: To present efficacy and safety of 0.19 mg fluocinolone acetonide insert (FAi) to treat chronic noninfectious uveitis (NIU) in a single referral center.
Methods: A retrospective observational clinical study of 11 eyes with NIU complicated by chronic cystoid macular edema (CMO).
Long-acting, slow-release injectable fluocinolone intravitreal implants have been approved for the treatment of non-infectious uveitis affecting the posterior segment. We summarise the development of intravitreal fluocinolone implants and discuss the technology including pharmacokinetics. We conducted a systematic review of evidence for the efficacy, safety and patient acceptability of fluocinolone 0.
View Article and Find Full Text PDFPurpose: To report on patients who needed hospitalization due to acute anterior uveitis (AAU) and within this group to compare clinical features and outcomes of treatment of HLA-B27+ and HLA-B27- AAU in the population of Slovenian patients.
Methods: Retrospective study of hospitalized patients with AAU in the last 39 months at the Eye Hospital in Ljubljana. The data of AAU patients were retroactively studied and compared on the basis of HLA-B27 antigen presence: visual acuity upon admission, visual outcome, the presence of hypopyon, fibrinous reaction, posterior iris synechiae, and complications, such as elevated intraocular pressure, cataract, and cystoid macular edema (CME).
Aim: A systematic review of miRNA profiling studies in uveitis.
Methods: Literature search strategy - Pubmed central central database, using miRNA/microRNA and intraocular inflammation/uveitis as keywords.
Results: We found twenty publications regarding the experimental and clinical use of miRNA in uveitis, published between 2011 and 2018.